Phase 2a study assessing colonization efficiency, safety, and acceptability of lactobacillus crispatus CTV-05 in women with bacterial vaginosis

Sexually Transmitted Diseases

Volumn 37, Issue 12, 2010, Pages 745-750

  Hemmerling, Anke ^a   Harrison, William ^a   Schroeder, Adrienne ^a   Park, Jeanna ^b   Korn, Abner ^a   Shiboski, Stephen ^a   Foster Rosales, Anne ^c   Cohen, Craig R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Planned Parenthood Golden Gate   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CTV 05; PLACEBO; PROBIOTIC AGENT; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL COLONIZATION; BACTERIAL GROWTH; CLINICAL ARTICLE; CLINICAL TRIAL; COLD; COLONY FORMING UNIT; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEMALE GENITAL PRURITUS; HEADACHE; HUMAN; LACTOBACILLUS; LACTOBACILLUS CRISPATUS; MUSCLE CRAMP; NAUSEA; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VAGINAL DISCOMFORT; VAGINAL ODOR; VAGINITIS;

ADMINISTRATION, INTRAVAGINAL; ADOLESCENT; ADULT; COLONY COUNT, MICROBIAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LACTOBACILLUS; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; PROBIOTICS; RECURRENCE; TREATMENT OUTCOME; VAGINA; VAGINOSIS, BACTERIAL; YOUNG ADULT;

EID: 78650276181     PISSN: 01485717     EISSN: None     Source Type: Journal    
DOI: 10.1097/OLQ.0b013e3181e50026     Document Type: Article

References (27)

1. Goldenberg RL, Klebanoff MA, Nugent R, et al. Vaginal Infections and Prematurity Study Group. Bacterial colonization of the vagina during pregnancy in four ethnic groups. Am J Obstet Gynecol 1996; 174:1618-1621.
2. Allsworth JE, Peipert JF. Prevalence of bacterial vaginosis: 2001- 2004 National Health and Nutrition Examination Survey data. Obstet Gynecol 2007; 109:114-120.
3. Bradshaw CS, Morton AN, Hocking J, et al. High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J Infect Dis 2006; 193:1478-1486.
4. Eschenbach DA, Hillier S, Critchlow C, et al. Diagnosis and clinical manifestations of bacterial vaginosis. Am J Obstet Gy-necol 1988; 158:819-828.
5. Hillier SL, Kiviat NB, Hawes SE, et al. Role of bacterial vagi-nosis-associated microorganisms in endometritis. Am J Obstet Gynecol 1996; 175:435-441.
6. Kurki T, Sivonen A, Renkonen OV, et al. Bacterial vaginosis in early pregnancy and pregnancy outcome. Obstet Gynecol 1992; 80:173-177.
7. Taha TE, Hoover DR, Dallabetta GA, et al. Bacterial vaginosis and disturbances of vaginal flora: Association with increased acquisition of HIV. AIDS 1998; 12:1699-1706.
8. Myer L, Denny L, Telerant R, et al. Bacterial vaginosis and susceptibility to HIV infection in South African women: A nested case-control study. J Infect Dis 2005; 192:1372-1380.
9. Cohen CR, Duerr A, Pruithithada N, et al. Bacterial vaginosis and HIV seroprevalence among female commercial sex workers in Chiang Mai, Thailand. AIDS 1995; 9:1093-1097.
10. Anukam K, Osazuwa E, Ahonkhai I, et al. Augmentation of antimicrobial metronidazole therapy of bacterial vaginosis with oral probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14: Randomized, double-blind, placebo controlled trial. Microbes Infect 2006; 8:1450-1454.
11. Rossi A, Rossi T, Bertini M, et al. The use of Lactobacillus rhamnosus in the therapy of bacterial vaginosis. Evaluation of clinical efficacy in a population of 40 women treated for 24 months. Arch Gynecol Obstet 2010; 281:1065-1069.
12. Larsson PG, Stray-Pedersen B, Ryttig KR, et al. Human lactobacilli as supplementation of clindamycin to patients with bacterial vagi-nosis reduce the recurrence rate; a 6-month, double-blind, randomized, placebo-controlled study. BMC Womens Health 2008; 8:3.
13. Bolton M, van der Straten A, Cohen CR. Probiotics: Potential to prevent HIV and sexually transmitted infections in women. Sex Transm Dis 2008; 35:214-225.
14. Cribby S, Taylor M, Reid G. Vaginal microbiota and the use of probiotics. Interdiscip Perspect Infect Dis 2008; 2008:256490.
15. Czaja CA, Stapleton AE, Yarova-Yarovaya Y, et al. Phase I trial of a Lactobacillus crispatus vaginal suppository for prevention of recurrent urinary tract infection in women. Infect Dis Obstet Gynecol 2007; 2007:35387.
16. Antonio MA, Meyn LA, Murray PJ, et al. Vaginal colonization by probiotic Lactobacillus crispatus CTV-05 is decreased by sexual activity and endogenous Lactobacilli. J Infect Dis 2009; 199: 1506-1513.
17. Hemmerling A, Harrison W, Schroeder A, et al. Phase 1 dose-ranging safety trial of Lactobacillus crispatus CTV-05 for the prevention of bacterial vaginosis. Sex Transm Dis 2009; 36:564-569.
18. Antonio MA, Hillier SL. DNA fingerprinting of Lactobacillus crispatus strain CTV-05 by repetitive element sequence-based PCR analysis in a pilot study of vaginal colonization. J Clin Microbiol 2003; 41:1881-1887.
19. Division of AIDS. DAIDS Toxicity Table Addendum for Vaginal Microbicide Studies (November 2007). Division of AIDS, 2007. http://rcc-beta.tech-res.com/ Document/safetyandpharmacovigilance/ Addendum-1-Female-Genital-Grading-Table-v1- Nov-2007.pdf. Accessed June 29 2010.
20. CONRAD/WHO. Manual for the standardization of colposcopy for the evaluation of vaginal products. 2004. Available at http:// www.conrad.org/ assets/attachments/Revised-Manual.PDF. Accessed February 19 2010.
21. Amsel R, Totten PA, Spiegel CA, et al. Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic associations. Am J Med 1983; 74:14-22.
22. Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. J Clin Microbiol 1991; 29:297-301.
23. Wallace A, Thorn M, Maguire RA, et al. Assay for establishing whether microbicide applicators have been exposed to the vagina. Sex Transm Dis 2004; 31:465-468.
24. FDA. Guidance for industry. Bacterial vaginosis- developing antimicrobial drugs for treatment; 1998. Available at: http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/ucm070969. pdf. Accessed February 24, 2010.
25. Eschenbach DA, Thwin SS, Patton DL, et al. Influence of the normal menstrual cycle on vaginal tissue, discharge, and micro-flora. Clin Infect Dis 2000; 30:901-907.
26. Riggs M, Klebanoff M, Nansel T, et al. Longitudinal association between hormonal contraceptives and bacterial vaginosis in women of reproductive age. Sex Transm Dis 2007; 34:954-959.
27. Austin MN, Rabe LK, Hillier SL. Limitations of the dye-based method for determining vaginal applicator use in microbicide trials. Sex Transm Dis 2009; 36:368-371.